Zobrazeno 21 - 30
of 811
pro vyhledávání: ''
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Complicated urinary tract infection (cUTI) is common among hospitalized patients. Though carbapenems are an effective treatment in the face of rising resistance, overuse drives carbapenem resistance (CR). We hypothesized that resistance to
Autor:
Eivind Galteland, Abdulkarim Hilli, Geir Mjøen, Ingvild Nordøy, Andreas Lind, Andreas Barratt-Due, Pål Aukrust, Magnus Holter Bjørkto, Christina Dörje
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-6 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background The use of complement inhibition is well established for complement mediated thrombotic microangiopathy, but its role in secondary forms of thrombotic microangiopathy is debated. We here present a case of thrombotic microangiopathy trigger
Autor:
Mária Fehérvári, Thomas F. E. Barth, Attila Patonai, Zsolt Káposztás, Tamás Strausz, Eszter Csulak, Áron Somorácz, Balázs Dezsényi, Z. Tolnai, Veronika Czoma, Tamás Sréter, András Csilek, Attila Oláh, Zsolt Dubóczki, Adriano Casulli, Beate Grüner, József Danka, Herbert Auer, Zoltán Széll, Kálmán Almási, Dénes Görög
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-15 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Human alveolar echinococcosis (AE) caused by Echinococcus multilocularis is an underreported, often misdiagnosed and mistreated parasitic disease mainly due to its low incidence. The aim of this study was to describe the epidemiological an
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study ent
Autor:
Maureen Kamene, Sylvia M LaCourse, Daniel Matemo, Zachary Feldman, John Kinuthia, David J. Horne, Jerphason Mecha, Ruanne V. Barnabas, Alex J Warr, Jill K. Gersh
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background People living with HIV (PLHIV) who reside in high tuberculosis burden settings remain at risk for tuberculosis disease despite treatment with anti-retroviral therapy and isoniazid preventive therapy (IPT). The performance of the World Heal
Autor:
Marie Helene Delbouille, Arnaud Ancion, Philippe Amabili, Jean-Olivier Defraigne, Melissa Van den Bulck, Vincent Tchana-Sato, Jean-Paul Lavigne, Philippe Delvenne, Elie Minga Lowampa, Marie-Pierre Hayette, Olivier Hougrand, Delphine Szecel, Isabelle Maquoi, Marc Senard, Charlotte Ponte, Julien Tridetti, Philippe Morimont, Natzi Sakalihasan, Olivier Detry, Patrizio Lancellotti
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background There are limited data on Coronavirus disease 2019 (COVID-19) in solid organ transplant patients, especially in heart transplant recipients, with only a few case reports and case series described so far. Heart transplant recipients may be
Autor:
Tom A Yates, Molebogeng X Rangaka, Marie Francis, Andre Charlett, Peter J White, V. Hack, Lara Goscé, Helen R. Stagg, Heinke Kunst, Laura Muñoz, Ibrahim Abubakar, Julian Surey, Marc Lipman
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Surey, J, Stagg, H R, Yates, T A, Lipman, M, White, P J, Charlett, A, Muñoz, L, Goscé, L, Rangaka, M X, Francis, M, Hack, V, Kunst, H & Abubakar, I 2021, ' An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England : the HALT LTBI pilot study ', BMC Infectious Diseases, vol. 21, 90 . https://doi.org/10.1186/s12879-021-05766-9
BMC INFECTIOUS DISEASES
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
BMC Infectious Diseases
Surey, J, Stagg, H R, Yates, T A, Lipman, M, White, P J, Charlett, A, Muñoz, L, Goscé, L, Rangaka, M X, Francis, M, Hack, V, Kunst, H & Abubakar, I 2021, ' An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England : the HALT LTBI pilot study ', BMC Infectious Diseases, vol. 21, 90 . https://doi.org/10.1186/s12879-021-05766-9
BMC INFECTIOUS DISEASES
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
BMC Infectious Diseases
Background Ending the global tuberculosis (TB) epidemic requires a focus on treating individuals with latent TB infection (LTBI) to prevent future cases. Promising trials of shorter regimens have shown them to be effective as preventative TB treatmen
Autor:
Ryuichi Takenaka, Kazuhiko Hashinaga, Shin-ichi Nureki, Haruka Fukuda, Teruo Sakamoto, Hideki Hayashidani, Takehiro Hashimoto, Osamu Shigemitsu
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Yersinia pseudotuberculosis infection can occur in an immunocompromised host. Although rare, bacteremia due to Y. pseudotuberculosis may also occur in immunocompetent hosts. The prognosis and therapeutic strategy, especially for immunocomp
Autor:
Yanling Li, Yang Han, Ling Xu, Wenxiu Peng, Taisheng Li, Qiang Fu, Xiaoli Du, Ting Zhu, Wei Cao, Xiaojing Song
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background The plasma concentration of patients treated with efavirenz (EFV) 600 mg was found to exceed the upper limit of the proposed therapeutic window in most Chinese HIV-infected individuals; thus, dosage reduction of EFV to 400 mg daily warrant
Autor:
L. Gayani Tillekeratne, Champica K Bodinayake, Gaya B Wijayaratne, Ruvini Kurukulasooriya, Tianchen Sheng, Pasangi Jayatissa, Christopher W. Woods, Helen L. Zhang, D. L. Bhagya Piyasiri, Ajith Nagahawatte
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Inappropriate antibiotic use is linked to the spread of antimicrobial resistance worldwide, but there are limited systemic data on antibiotic utilization in low- and middle-income countries. The purpose of this study was to evaluate the pr